Caplin Point Labs News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Caplin Point Laboratories Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Caplin Point Laboratories Ltd.
Rating: 5
Author: ICICI Direct

Keep track of all breaking news and updates on Caplin Point Labs from all sources in a single place.

Caplin Point Laboratories Ltd.

06 Apr 2026

1704.10

2.53%

Company Update

Caplin Point Laboratories Ltd - 524742 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026

pdf

Caplin Point Laboratories Ltd.

27 Mar 2026

1704.10

2.53%

SAST

Caplin Point Laboratories Ltd - 524742 - Closure of Trading Window

BSE India

Intimation of closure of Trading Window commencing from April 01, 2026

pdf

Caplin Point Laboratories Ltd.

13 Mar 2026

1704.10

2.53%

Company Update

Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press release regarding receipt of final approval by our subsidiary, Caplin Steriles Limited, from USFDA for the Potassium Phosphates Injection USP

pdf

Caplin Point Laboratories Ltd.

03 Mar 2026

1704.10

2.53%

Company Update

Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Cessation

BSE India

Cessation of Dr. C K Gariyali as an Independent Director of the Company with effect from March 3, 2026.

pdf

Caplin Point Laboratories Ltd.

28 Feb 2026

1704.10

2.53%

Company Update

Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from USFDA for the Desmopressin Acetate Injection USP

pdf

Caplin Point Laboratories Ltd.

24 Feb 2026

1704.10

2.53%

Company Update

Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press release regarding receipt of final approval by our Subsidiary, Caplin Steriles Limited, from the USFDA for the Sodium Phosphates Injection USP

pdf

Caplin Point Laboratories Ltd.

11 Feb 2026

1704.10

2.53%

Earnings Call

Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Transcript of the Earnings Call - Q3 - FY 2025-26

pdf

Caplin Point Laboratories Ltd.

06 Feb 2026

1704.10

2.53%

Caplin Point Laboratories

Buy: Caplin Point Laboratories ...

Target

ICICI Direct

Caplin Steriles caters mainly to the US and other regulated markets. So far, it has developed and filed 52 ANDAs in the US on its own and with partners, with 42 approvals as on date. The Company is also working on a portfolio of 40+ simple and complex Injectable and Ophthalmic products,...